Kevetrin is under clinical development by Innovation Pharmaceuticals and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase II drugs for Epithelial Ovarian Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Kevetrin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Kevetrin overview

Kevetrin (4-Isothioureidobutyronitrile hydrochloride, Kevetrin hydrochloride) is under development for the treatment of pediatric retinoblastoma, metastatic pancreatic cancer, acute myeloid leukemia and platinum-resistant/refractory epithelial ovarian cancer. It is a new chemical entity. The drug candidate is administered as an intravenous infusion and through the oral route. The drug candidate acts by targeting p53. It was also under development for the treatment of thymoma, prostate cancer, non-small cell lung cancer, head and neck cancer squamous cell carcinoma, endometrial cancer, cervical cancer, small-cell lung cancer, metastatic renal cell carcinoma, transitional cell cancer (urothelial cell cancer), bladder cancer, metastatic melanoma, bile duct cancer (cholangiocarcinoma), metastatic liposarcoma, parotid myoepithelial cancer, metastatic adenoid cystic cancer of trachea, atypical intradermal spindle cell neoplasm of scalp, breast cancer, colorectal adenocarcinoma, glioblastoma multiforme and metastatic pulmonary basal cell carcinoma.

Innovation Pharmaceuticals overview

Innovation Pharmaceuticals, formerly Cellceutix, is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company provides pipeline products such as kevetrin for the treatment of advanced solid tumors and acute myelogenous leukemia, among others. Innovation Pharmaceuticals offers pipeline products such as Brilacidin for the treatment of oral mucositis and skin infections; and Prurisol for the treatment of psoriasis. It works in collaboration with various research institutions across the US and other European countries. Innovation Pharmaceuticals is headquartered in Beverly, Massachusetts, the US.

For a complete picture of Kevetrin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.